Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects, aged ≥ 18 years;~* MSSA bacteraemia: ≥ 1 positive blood culture(s) for MSSA in the first 72 h up to randomisation in patients with clinical suspicion of infection;~* Written informed consent of the participant or the legal representative.~Exclusion Criteria:~* Severe clinical status with expected death \<48h.~* Severe hepatic cirrhosis (Child-Pugh C).~* Moderate-severe cardiac chronic failure (NYHA III-IV).~* Prosthetic endocarditis (need for concomitant antibiotic therapy active against S. aureus together with the study antibiotics for the first 7 days of the study).~* No pre-existing evidence of S. aureus fosfomycin non-susceptibility.~* Known hypersensitivity to cloxacillin or fosfomycin.~* Polymicrobial bacteraemia with more than one microorganism in blood cultures.~* A positive pregnancy test or pregnancy or lactation at the time of inclusion.~* Miastenia gravis.~* Participation in another clinical trial.~* Previous participation in the present clinical trial.~* Acute SARS-CoV2 infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination therapy group (Type: EXPERIMENTAL): intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment
- Standard therapy group (Type: ACTIVE_COMPARATOR): intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).